Company Overview: Protea

About the Company Mail

Protea
Facebook Tweeter

Protea is a leader in the emerging field of Bioanalytics. The company develops new technology for the identification, characterization, and quantitation of biologically-important molecules for basic research, pharmaceutical development, and diagnostic applications.

Bioanalytics is the direct identification and characterization of the products of all living cells, including proteins, lipids, metabolites and nucleic acids. Bioanalytics is emerging as a crucial area, where new technology is needed to support the future of medical research, and virtually every other field of life science research.

We develop new bioanalytical methods that enable the direct analysis of proteins and other biomolecules, and apply our capabilities to support your laboratory’s research objectives.


Investor Toolkit

Multimedia

Company News

  • Protea Extends Collaboration with Protein Metrics

    MORGANTOWN, W.Va., Jan. 18, 2017 (GLOBE NEWSWIRE) — Protea Biosciences Group, Inc. (PRGB) (“Protea”) announced today that the Company has signed a renewal of its collaboration with California-based Protein Metrics Inc. for further applications development of their advanced analytical...

  • Protea In Marketing Partnership with MatTek Corp.

    MORGANTOWN, W.Va., Jan. 10, 2017 (GLOBE NEWSWIRE) — Protea Biosciences Group, Inc. (PRGB) (“Protea”) announced today that the Company has entered into a co-marketing agreement with MatTek Corporation (“MatTek”), which allows Protea to include MatTek’s human cell based in...

  • Protea Announces Third Quarter 2016 Results

    MORGANTOWN, W.Va., Nov. 22, 2016 (GLOBE NEWSWIRE) — Protea Biosciences Group, Inc. (PRGB) (“Protea”) released its Third Quarter 2016 results today, reporting revenue of $519,908 for the quarter, and revenue for the first nine months of 2016 of $1,577,010,...

  • LAESI® technology used in antibacterial research

    MORGANTOWN, W.Va., Oct. 19, 2016 (GLOBE NEWSWIRE) — Protea Biosciences Group, Inc. (PRGB) (“Protea”) announced today the use of the Company’s proprietary LAESI technology to provide rapid profiling of a bacteria’s resistance to antibiotics. The results were recently published...

Email Subscription

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address